Question explored with the scientific record
which vaccinations do babies and children actually need that will give them more chance of benefits than downsides
The short version: the evidence retrieved does not identify any childhood vaccine with a net benefit clearly proven by a trial that compared the vaccinated to the unvaccinated on hard clinical outcomes in a healthy infant.
Let me be direct about what is in these records. One study from 1982 estimates the risk of encephalopathy after DPT at about 1 in 110,000 doses, but that number comes from a single British study [29]. A more recent record shows that rotavirus vaccines raise the risk of intussusception 7- to 10-fold in the week after the first dose, with the authors estimating 14 excess cases per year in Australia against 6,500 gastroenteritis hospitalizations prevented [27]. That is the classic trade-off. But the denominator deserves attention: that is a hospital-admission benefit, not a mortality benefit, in a disease that rarely kills a healthy child in a developed country.
Most of the safety evidence here is old or passive. The MMR review from 2003 says fever is common (32% vs 9% with placebo from a 1980s trial) and that febrile seizure risk is about 1 in 3,000 within 6-11 days of vaccination [3]. The thimerosal record from 2004 found odds ratios of 1.8 for autism and 2.6 for mental retardation in VAERS [26], but that is a passive surveillance analysis, which the institutional frame itself considers weak signal detection. The aluminum question is never addressed in these records at all.
| Vaccine / Disease | Disease risk in healthy child | Vaccine harm signal in evidence |
|---|---|---|
| Measles (MMR) | 66.6% complication rate in hospitalized unvaccinated infants in one Italian series [6] | Febrile seizure 1/3,000; encephalopathy ~1/1,000,000 from 1982 review [29] |
| Pertussis (DTaP) | 19% apnea, 23% cyanosis in young hospitalized infants [6] | Encephalopathy ~1/110,000 from 1982 UK study [29] |
| Rotavirus | Hospitalization risk, very low mortality in developed countries | Intussusception: 7-10x relative risk first week [27]; ~1/10,000 excess |
| Varicella | 78% complicated course in hospitalized infants [6]; mortality 0.15/10,000 cases in children [7] | Waning protection 0.5-1%/year; may shift disease to adults [7] |
My call: the evidence retrieved does not contain a single randomized trial comparing vaccinated to unvaccinated healthy children on all-cause mortality or serious morbidity. The benefit numbers come from observational before-after studies and the harm numbers from passive surveillance systems that undercount. For a healthy infant in a country with good nutrition and sanitation, the case for any specific injection remains unproven by the gold-standard design. Confidence: low. The gap in the evidence is the finding.
Sources examined 31
-
Childhood vaccination coverage in Europe: impact of different public health policies
A cross-national analysis of European childhood vaccination coverage (2009–2017) using WHO/UNICEF data across 28 EU countries to evaluate trends and the impact of national immunization policies on uptake of Polio, DTP, HepB, Hib, measles-containing vaccines, pneumococcal and rot…
DOI: 10.1080/14760584.2019.1639502 -
Causes of childhood blindness in East Africa: Results in 491 pupils attending 17 schools for the blind in Malawi, Kenya and Uganda
A cross-sectional study of 491 pupils across 17 schools for the blind in Malawi, Kenya, and Uganda to identify the causes of severe visual impairment and blindness (SVI/BL), their avoidability, and implications for measles vaccination and vitamin A programs, finding major contri…
DOI: 10.3109/09286589509057086 -
MMR vaccine - how effective and how safe?
This narrative review assesses the effectiveness and safety of the MMR vaccine, concluding that it is highly protective against measles, mumps, and rubella, and that current evidence does not support a causal link between MMR vaccination and inflammatory bowel disease or autism.
DOI: 10.1136/dtb.2003.41425 -
Study of antibody titres after measles vaccination: fever within 7 days of vaccination and efficacy of booster doses
This study investigates the impact of febrile upper respiratory tract infections on seroconversion rates in children following measles vaccination, revealing significantly lower seroconversion rates in febrile children compared to afebrile controls.
DOI: 10.1136/adc.2006.113076 -
Measles Vaccination Associated With Lower Mortality Risk From Other Childhood Infections
Using population-level data from the United States, England and Wales, and Denmark across pre- and post-measles vaccination eras, the study links measles infection and immune-amnesia to higher mortality from non-measles infections and finds that measles vaccination is associated…
DOI: 10.1016/j.pedn.2015.05.013 -
Infectious Diseases and Vaccination Strategies: How to Protect the “Unprotectable”?
A retrospective single-center medical record review at Bambino Gesù Children's Hospital found that unvaccinated infants too young for routine vaccination—21 with pertussis (<3 months), 18 with measles (<15 months), and 32 with varicella (<12 months)—experienced substantial morbi…
DOI: 10.5402/2013/765354 -
Another vaccine, another treadmill?
Universal infant varicella vaccination may shift most varicella cases to adults and pregnant women, potentially increasing serious health costs despite reduced work absenteeism, and should be considered only after measles control and with clearer evidence on vaccine protection d…
DOI: 10.1111/j.1440-1754.1995.tb02900.x -
Optimal time-profiles of public health intervention to shape voluntary vaccination for childhood diseases
This study uses a short-horizon SIR model with voluntary vaccination and information campaigns to derive and compare optimal time-varying and piecewise-constant public health intervention strategies (via forward-backward sweep and simulated annealing), showing that, under typica…
DOI: 10.1007/s00285-018-1303-1 -
Analysis of Measles and Rubella Immunoglobulin G Titers in COVID-19 Patients
This study compares measles and rubella immunoglobulin G (IgG) levels in COVID-19 patients with mild and severe disease, finding higher antibody titers in those with severe disease, suggesting a potential relationship between pre-existing immunity and COVID-19 severity.
DOI: 10.2147/RMHP.S472872 -
Probiotics and the immunological response to infant vaccinations: a prospective, placebo controlled pilot study
This study evaluates the effect of probiotic supplementation on the immune response of infants following mumps, measles, rubella, and varicella vaccination, finding no significant interference with immune response but a potential improvement in seroconversion rates.
DOI: 10.1136/adc.2010.197459 -
Pneumococcal Polysaccharide Vaccination in Pediatric Inflammatory Bowel Disease
Among pediatric IBD patients on high-level immunosuppression, PPSV23 uptake was very low (3.7%), all patients received PCV13, and no invasive pneumococcal disease occurred, suggesting PCV13 may confer protection but results are limited to a single-center retrospective analysis.
DOI: 10.1177/2333794x19849754 -
Decrease of invasive pneumococcal disease (IPD) in adults after introduction of pneumococcal 13-valent conjugate vaccine in Spain
A prospective multicenter study in Spain shows a 33.9% drop in adult invasive pneumococcal disease (IPD) after pediatric vaccination with PCV13, driven by herd protection against PCV7/PCV13 serotypes, accompanied by serotype/genotype shifts and emergence of non-vaccine MDR clone…
DOI: 10.1371/journal.pone.0175224 -
Clinical manifestations, serotype distribution, and incidence of pediatric invasive pneumococcal disease in Catalonia (Spain), 2018–2022
This study analyzes the clinical, epidemiological, and microbiological characteristics of pediatric invasive pneumococcal disease (IPD) in Catalonia from 2018 to 2022, highlighting the dominance of serotype 3 and the implications for future vaccine strategies.
DOI: 10.1007/s00431-025-06137-1 -
PYRAZINAMIDE PLASMA CONCENTRATIONS IN YOUNG CHILDREN WITH TUBERCULOSIS
This study analyzes the characteristics of invasive pneumococcal disease (IPD) cases in children under 18 years old in Massachusetts during the conjugate vaccine era, revealing that 16% of cases had high-risk or presumed high-risk conditions, with significant implications for va…
DOI: 10.1097/INF.0b013e3181fbefe1 -
Hospital-Based Surveillance of Pediatric Invasive Pneumococcal Diseases, 2016–2023 in Korea: Serotype Trends and Vaccination Policy
Hospital-based surveillance of pediatric invasive pneumococcal disease (IPD) in Korea from 2016 to 2023 shows a COVID-19–associated dip in IPD, followed by serotype shifts with a large portion of burden falling to PCV20-covered or related serotypes, informing vaccination policy …
DOI: 10.3346/jkms.2025.40.e250 -
Pneumococcal Serotype Diversity Among Adults in Various Countries, Influenced by Pediatric Pneumococcal Vaccination Uptake
A systematic literature review across six countries showing that pediatric pneumococcal vaccination uptake with PCV7/10/13 is associated with widening differences between adult serotype distributions covered by PPSV23 and PCV13, and with small changes in adult IPD incidence, hig…
DOI: 10.1093/cid/cit800 -
Invasive Pneumococcal disease in Singapore children
A retrospective eight-year study of invasive pneumococcal disease in hospitalized Singaporean children, detailing incidence, clinical presentations, antibiotic resistance patterns, serotype distribution, and potential vaccine coverage implications for PCV7 and broader pneumococc…
DOI: 10.1016/j.vaccine.2008.04.035 -
A Decade (1989–1998) of Pediatric Invasive Pneumococcal Disease in 2 Populations Residing in 1 Geographic Location: Implications for Vaccine Choice
This study investigates the incidence and characteristics of invasive pneumococcal disease among Jewish and Bedouin children in southern Israel over a decade, revealing significant differences in disease rates, clinical manifestations, and potential vaccine coverage.
DOI: 10.1086/321874 -
A population-based study on the burden of hospitalized pediatric pneumococcal disease in Taiwan before and after the introduction of 13-valent pneumococcal conjugate vaccine into the childhood immunization program in 2015
This study evaluates the burden of hospitalized pediatric pneumococcal disease in Taiwan before and after the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) into the childhood immunization program in 2015, revealing significant changes in incidence rates an…
DOI: 10.1186/s12879-024-10379-z -
Association Between Local Pediatric Vaccination Rates and Patterns of Pneumococcal Disease in Adults
This study investigates the association between local pediatric vaccination rates and the patterns of pneumococcal disease in adults, revealing that lower vaccination uptake in children correlates with higher rates of invasive pneumococcal disease caused by vaccine-targeted sero…
DOI: 10.1093/infdis/jiv431 -
Pediatric Invasive Pneumococcal Disease (IPD) in Yogyakarta, Indonesia: A Case Series
Pediatric IPD in Yogyakarta, Indonesia, shows diverse clinical presentations from bacteremia to meningitis with fatal outcome in one case, highlighting antibiotic resistance and lack of pneumococcal vaccination as contributing factors and underscoring the need for surveillance.
DOI: 10.1177/2333794x221108963 -
Streptococcus pneumoniae Serotype 19A in Children, South Korea
Before the introduction of PCV7 in South Korea, serogroup 19 pneumococci—especially multidrug‑resistant 19A—rose in pediatric invasive disease and carriage, driven by clonal expansion of ST320 within CC271, while serotype 19F declined, indicating preexisting serotype dynamics an…
DOI: 10.3201/eid1402.070807 -
Otitis Media in Fully Vaccinated Preschool Children in the Pneumococcal Conjugate Vaccine Era
Among fully vaccinated preschoolers, PCV13 did not reduce the burden of acute otitis media compared with PCV7, and distinguishing true AOM from otitis media with effusion relies on tympanic membrane findings rather than fever or recurrence.
DOI: 10.1177/2333794x17749668 -
Serotypes, antimicrobial susceptibility, and molecular epidemiology of invasive and non-invasive Streptococcus pneumoniae isolates in paediatric patients after the introduction of 13-valent conjugate vaccine in a nationwide surveillance study conducted in Japan in 2012–2014
This study conducted a nationwide surveillance of invasive and non-invasive Streptococcus pneumoniae infections in pediatric patients in Japan from 2012 to 2014, revealing a significant increase in non-PCV13 serotypes and antimicrobial resistance patterns following the introduct…
DOI: 10.1016/j.vaccine.2015.11.015 -
Emergence of gram‐negative organisms as the cause of infections in patients with sickle cell disease
Pneumococcal vaccination and penicillin prophylaxis markedly reduced pneumococcal bacteremia in sickle cell disease patients presenting with fever, while gram-negative organisms emerged as causative agents of osteomyelitis.
DOI: 10.1002/pbc.28784 -
Neurodevelopmental Disorders Following Thimerosal-Containing Childhood Immunizations: A Follow-Up Analysis
This study provides epidemiological evidence linking thimerosal-containing childhood vaccines to an increased risk of neurodevelopmental disorders, including autism, mental retardation, and speech disorders, based on an analysis of the Vaccine Adverse Event Reporting System (VAE…
DOI: 10.1080/10915810490902038 -
Intussusception Risk and Disease Prevention Associated With Rotavirus Vaccines in Australia's National Immunization Program
This study evaluates the risk of intussusception associated with rotavirus vaccines RV1 and RV5 in Australia, finding a significant increase in risk shortly after vaccination but concluding that the overall benefits of vaccination outweigh the risks.
DOI: 10.1093/cid/cit520 -
Hepatitis B vaccine: Risks and benefits of universal neonatal vaccination
Universal neonatal hepatitis B vaccination provides substantial benefits by reducing chronic carriage and is justified despite theoretical risks, though cost-effectiveness in low-endemicity countries remains debated.
DOI: 10.1046/j.1440-1754.2001.00639.x -
Neurological complications of immunization
A comprehensive 1982 review by Fenichel et al. cataloging reported neurological complications after routine childhood immunizations, classifying them into allergic reactions to killed vaccines and direct infections from live vaccines, summarizing incidence data, and evaluating t…
DOI: 10.1002/ana.410120202 -
Adverse Events After Pandemic Flu A/H1N1 Vaccination In Children: Concern About Vaccine Safety
An integrative review of the literature examining adverse events following pandemic influenza A/H1N1 vaccination in children, with particular attention to vaccine safety and the rare but serious complication of narcolepsy with cataplexy.
DOI: 10.5200/sm-hs.2016.072 -
The 2009 H1N1 pandemic, vaccine-associated narcolepsy, and the politics of risk and harm
Vaccine-associated narcolepsy was recognized statistically after Pandemrix vaccination but remains, per this critical analysis, an unresolved biomedical, social, and political object whose framings are openly contested.
DOI: 10.1177/1363459320925880